公开(公告)号：WO2014071082A2

公开(公告)日：2014-05-08

申请号：PCT/US2013/067890

申请日：2013-10-31

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  PRICE, Nathan, D. ,  HOOD, Leroy ,  SUNG, Jaeyun ,  GEMAN, Donald

Inventor： PRICE, Nathan, D. ,  HOOD, Leroy ,  SUNG, Jaeyun ,  GEMAN, Donald

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: The invention provides methods to identify various types of brain cancer tissue by comparing gene expression transcriptomes in tissue samples. A sequential method to discriminate among six different types of brain cancer is described.

Abstract translation: 本发明提供通过比较组织样品中的基因表达转录组来鉴定各种类型的脑癌组织的方法。 描述了区分六种不同类型的脑癌的顺序方法。

公开(公告)号：WO2014039893A1

公开(公告)日：2014-03-13

申请号：PCT/US2013/058608

申请日：2013-09-06

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  HOOD, Leroy ,  WANG, Kai ,  LEE, Inyoul ,  ZHOU, Yong ,  CHO, Ji Hoon ,  GHOSH, Dhimankrishna

Inventor： HOOD, Leroy ,  WANG, Kai ,  LEE, Inyoul ,  ZHOU, Yong ,  CHO, Ji Hoon ,  GHOSH, Dhimankrishna

IPC: C12Q1/68

CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: Concentrations of certain miRNA, mRNA and/or protein markers in the biological fluids and/or tissues of a subject are used to determine the probability that the subject does or does not have Posttraumatic Stress Disorder (PTSD). The concentrations of these markers in fluids and/or tissues are different in subjects with PTSD as compared to subjects who do not suffer from this disorder.

Abstract translation: 使用受试者的生物流体和/或组织中某些miRNA，mRNA和/或蛋白质标记物的浓度来确定受试者做或不具有创伤后应激障碍（PTSD）的可能性。 与不患有这种疾病的受试者相比，这些标记物在流体和/或组织中的浓度与具有PTSD的受试者不同。

公开(公告)号：WO2011038400A1

公开(公告)日：2011-03-31

申请号：PCT/US2010/050564

申请日：2010-09-28

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  TIAN, Qiang ,  FOLTZ, Greg, D. ,  HOOD, Leroy ,  YAN, Xiaowei

Inventor： TIAN, Qiang ,  FOLTZ, Greg, D. ,  HOOD, Leroy ,  YAN, Xiaowei

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118

Abstract: Signatures indicative of cancer grades are based on over- and under-expression of 214 genes that characterize expression patterns in CD133+ cells.

Abstract translation: 指示癌症等级的签名是基于表征CD133 +细胞中表达模式的214个基因的过表达和低表达。

公开(公告)号：WO2009101181A2

公开(公告)日：2009-08-20

申请号：PCT/EP2009/051721

申请日：2009-02-13

Applicant: UNIVERSITE LIBRE DE BRUXELLES ,  EUROGENTEC ,  INSTITUTE FOR SYSTEMS BIOLOGY ,  EIZIRIK, Decio L. ,  FLAMEZ, Daisy ,  SALMON, Isabelle ,  BERTON, Alix ,  ROLAND, Isabelle ,  MARECHAL, Daniel ,  BECKERS, Marie-Claire ,  HOOD, Leroy ,  GOODMAN, Nathan ,  KUTLU, Burak

Inventor： EIZIRIK, Decio L. ,  FLAMEZ, Daisy ,  SALMON, Isabelle ,  BERTON, Alix ,  ROLAND, Isabelle ,  MARECHAL, Daniel ,  BECKERS, Marie-Claire ,  HOOD, Leroy ,  GOODMAN, Nathan ,  KUTLU, Burak

IPC: C12N5/06 ,  C07K14/00 ,  G01N33/00

CPC classification number: G01N33/573 ,  C07K14/705 ,  G01N33/57438 ,  G01N2800/042

Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1 ) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.

Abstract translation: 本发明涉及特异性位于胰β细胞质膜中的生物标志物的鉴定。 它是通过系统生物学方法在人胰岛获得的大规模并行信号测序数据集和人胰岛，纯化的大鼠原代β和非β细胞和胰岛素瘤细胞的Affymetrix微阵列数据集中选择的。 基于一组具体特征，生物标志物是研究胰腺β细胞在健康和疾病（T1D，T2D，胰腺癌，肥胖，胰岛移植，β细胞再生）中成像和靶向策略的独特候选。 所选生物标志物的五个特征是：1）与周围组织相比，胰岛中优先表达; 2）胰腺β细胞中的表达高于胰腺α细胞或其他胰岛非β细胞; 3）胰腺β细胞中的表达水平较高，或与胰腺β细胞特异性表达的酶的葡萄糖激酶相当; 4）位于膜中并且因此可靶向抗体，肽或小分子，其允许成像，靶向和免疫组织化学; 和5）在β细胞质量的炎症过程中不诱导表达，并且蛋白质不富含T细胞和树突状细胞或参与炎症过程的其他细胞中。

公开(公告)号：WO2020209988A9

公开(公告)日：2020-10-15

申请号：PCT/US2020/023028

申请日：2020-03-16

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH ,  U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND ,  ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ,  NEW YORK UNIVERSITY ,  MCLEAN HOSPITAL CORPORATION ,  GENEVA FOUNDATION

Inventor： DEAN, Kelsey R. ,  DOYLE III, Francis J. ,  MELLON, Synthia H. ,  WOLKOWITZ, Owen M. ,  LEE, Inyoul ,  HOOD, Leroy ,  YANG, Ruoting ,  HAMMAMIEH, Rasha ,  JETT, Marti ,  YEHUDA, Rachel ,  MARMAR, Charles R. ,  RESSLER, Kerry J. ,  GAUTAM, Aarti ,  FLORY, Janine ,  WANG, Kai

IPC: C12Q1/686

Abstract: The invention described is directed to a method to treat PTSD in a subject which method includes identifying the subject as suffering from PTSD or likely to suffer from PTSD by virtue of assessing one or more of the markers set forth herein, and treating the subject thus identified.

公开(公告)号：WO2015200823A1

公开(公告)日：2015-12-30

申请号：PCT/US2015/038043

申请日：2015-06-26

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY

Inventor： GHOSH, Dhimankrishna ,  COBBS, Charles, S. ,  PRICE, Nathan, D. ,  HOOD, Leroy

IPC: G01N33/574

CPC classification number: G01N33/57407 ,  A61K39/00 ,  G01N33/57484 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56

Abstract: A signature of proteins occurring in glioblastoma multiforme (GBM) tissue comprised of 33 cell surface proteins (GBMSig) that distinguish subjects with GBM from healthy controls with more than 98% accuracy is described. In addition, four of the members of this signature are particularly useful as blood-borne markers of GBM. Certain other members of the signature are indicators of the possible efficacy of the use of TGF-βΙ inhibitors in the treatment of this condition. Methods to treat and to stratify GBM based on GBMSig proteins are also disclosed.

Abstract translation: 描述了以多于98％准确度区分患者与健康对照组的患者与33个细胞表面蛋白（GBMSig）组成的胶质母细胞瘤多形性（GBM）组织中发生的蛋白质的特征。 此外，该签名的四名成员特别适用于GBM的血源标记。 签名的某些其他成员是使用TGF-β1抑制剂治疗这种病症的可能功效的指标。 还公开了基于GBMSig蛋白处理和分层GBM的方法。

公开(公告)号：WO2014144806A1

公开(公告)日：2014-09-18

申请号：PCT/US2014/029367

申请日：2014-03-14

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  BROGAARD, Kristin ,  LAUSTED, Christopher ,  HOOD, Leroy

Inventor： BROGAARD, Kristin ,  LAUSTED, Christopher ,  HOOD, Leroy

IPC: C07H21/04

CPC classification number: G01N33/58 ,  G01N33/5017

Abstract: The invention provides an efficient multiplex method for identifying binding partners of small molecules and proteins. The small molecules and proteins are tagged with a nucleic acid barcode that can be used to identify the protein or small molecule, and thereby its partner.

Abstract translation: 本发明提供了用于鉴定小分子和蛋白质的结合伴侣的有效多重方法。 小分子和蛋白质用可用于鉴定蛋白质或小分子的核酸条形码，从而标记其配偶体。

公开(公告)号：WO2008021290A2

公开(公告)日：2008-02-21

申请号：PCT/US2007/017868

申请日：2007-08-09

Applicant: HOMESTEAD CLINICAL CORPORATION ,  INSTITUTE FOR SYSTEMS BIOLOGY ,  HOOD, Leroy ,  BECKMANN, Patricia, M. ,  JOHNSON, Richard ,  MARELLI, Marcello ,  LI, Xiaojun

Inventor： HOOD, Leroy ,  BECKMANN, Patricia, M. ,  JOHNSON, Richard ,  MARELLI, Marcello ,  LI, Xiaojun

IPC: C12Q1/00

CPC classification number: G01N33/68 ,  G01N33/6845 ,  G01N2800/00 ,  G01N2800/52

Abstract: The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological tissue or other biological fluid.

Abstract translation: 本发明一般涉及鉴定和使用器官特异性蛋白质和转录物的方法。 本发明进一步提供了包含器官特异性蛋白质和编码其的转录物的组合物，用于检测这些蛋白质和转录物的检测试剂以及用于测量血液，生物组织或其他生物学流体中的器官特异性蛋白质/转录物的诊断板，试剂盒和阵列